SCHEMBL16413800

SCHEMBL16413800

CC(C)(C)OC(=O)N1CCC(O)(C(=O)O)C1=O

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 1/20 0.40
▸ PDE4A P27815 4/20 0.37
▸ PDE4B Q07343 4/20 0.37
▸ PDE4C Q08493 4/20 0.37
▸ PDE4D Q08499 4/20 0.37
▸ USP2 O75604 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.36
▸ GRIN2B Q13224 1/20 0.35
▸ GRIN2C Q14957 1/20 0.35
▸ NR1H2 P55055 3/20 0.33
▸ RXRA P19793 2/20 0.33
▸ NR1H3 Q13133 2/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ RORC P51449 1/20 0.33
▸ DDB1 Q16531 1/20 0.33
▸ CRBN Q96SW2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16414073 0.87 KDM1A (0.41) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL25248764 0.81 KDM1A (0.40) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL3733424 0.81 KDM1A (0.42) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL479856 0.79 KDM1A (0.43) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL20456330 0.79 KDM1A (0.43) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL27192628 0.78 KDM1A (0.42) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL15325414 0.77 DDB1 (0.49) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL25232243 0.76 KDM1A (0.41) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL21408126 0.76 KDM1A (0.41) KDM1APDE4APDE4BPDE4CPDE4D
SCHEMBL23388831 0.76 KDM1A (0.41) KDM1APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2834221-B1 CYCLIC AMIDES AS METAP-2 INHIBITORS MERCK PATENT GMBH (DE) 2016-05-25 — — EP claimed
US-10093623-B2 Cyclic amides as MetAP-2 inhibitors MERCK PATENT GMBH (DE) 2018-10-09 — — US disclosed
US-20150031670-A1 CYCLIC AMIDES AS METAP-2 INHIBITORS MERCK PATENT GMBH (DE) 2015-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093623-B2 Cyclic amides as MetAP-2 inhibitors METAP2, METAP1, LNPEP KDM1A 3005/4885PDE4A 2242/4885PDE4B 2221/4885
US-20150031670-A1 CYCLIC AMIDES AS METAP-2 INHIBITORS METAP2, METAP1, ENPEP KDM1A 1924/4885PDE4A 2627/4885PDE4B 2672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback